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View for Imaging of Atherosclerosis?*
Robert J. Gropler, MDSEE PAGE 121N oninvasive imaging plays a central rolein the management of the patient withatherosclerosis. It provides key pieces of in-
formation regarding disease detection, severity, pro-
gression, and regression. Indeed, the importance of
noninvasive imaging is highlighted by the continued
reﬁnement and amalgamation of various advanced
imaging technologies into hybrid devices and the
development of novel contrast agents. However,
these technical advancements in large part still
focus on the enhancement and integration of the
detection, localization, and characterization of the
atherosclerotic plaque and its downstream sequelae.
Yet atherosclerosis is inherently a systemic disease
characterized by a dynamic immune-inﬂammatory
process typiﬁed by cycles of intense activity and pro-
gression followed by intervals of stabilization. Conse-
quently, major contributors to the atherosclerotic
process arise from sites upstream from the athero-
sclerotic plaque. For example, macrophage accumula-
tion in the arterial wall via initial differentiation from
circulating monocytes or their subsequent local pro-
liferation is fundamental to atherosclerotic plaque
formation (1,2). The circulating monocytes are pro-
duced by hematopoietic stem and multipotential
progenitor cells in the bone marrow and other extra-
medullary organs such as the spleen. From a clinical
perspective, numerous studies have demonstrated
that proinﬂammatory conditions manifesting as leu-
kocytosis, particularly monocytosis, are associated
with an adverse cardiovascular outcome. In patients
without pre-existing atherosclerosis, the monocyte
count is an independent predictor of future carotid
plaque formation at 7 years of follow-up (3).*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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(ACS), it appears leukocytosis and an elevated
C-reactive protein level are associated with a wors-
ening 6-month prognosis (4).
Based on the results of pre-clinical studies, a
paradigm has been proposed that an acute ischemic
event, such as a myocardial infarction (MI), results in
increased sympathetic nervous system signaling,
which liberates hematopoietic stem and progenitor
cells from the bone marrow. These progenitors then
travel to the spleen, where they boost monocyte
production and activation. The subsequent mono-
cytosis results in atherosclerotic plaque expansion
(5). This paradigm has been termed the cardiosplenic
axis. The paradigm provides an explanation for the
monocyte trafﬁcking patterns and their mechanistic
basis for the acceleration of atherosclerosis. Recently,
the presence of increased arterial inﬂammation and
its association with both bone marrow and spleen
metabolic activity were conﬁrmed in humans after
MI on the basis of imaging with positron emission
tomography/computed tomography with 18F-ﬂuo-
rodeoxyglucose (6).The paper in this issue of iJACC by Emami et al. (7)
attempts to provide greater texture to this concept of
a cardiosplenic axis. Their report consists of 2 studies.
The goal of the ﬁrst study was to determine whether
metabolic activity of the bone marrow and spleen was
associated with systemic inﬂammation, proin-
ﬂammatory leukocyte remodeling, and arterial wall
inﬂammation in patients after an ACS event. Positron
emission tomography with 18F-ﬂuorodeoxyglucose to
measure metabolic activity in the bone marrow and
spleen and inﬂammation in the arterial wall (left and
right carotid arteries and aorta) was compared with
serum biomarkers for systemic inﬂammation and
proinﬂammatory gene expression of circulating leu-
kocytes. The measurements were obtained in 22 pa-
tients with documented ACS and 22 patients with
documented atherosclerosis but without ACS. It was
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132observed that bone marrow and splenic 18F-ﬂuo-
rodeoxyglucose activity was higher in ACS patients
than in non-ACS patients and directly correlated with
arterial 18F-ﬂuorodeoxyglucose uptake and serum
levels of C-reactive protein, a marker of systemic
inﬂammation. Bone marrow and splenic 18F-ﬂuo-
rodeoxyglucose uptake also directly correlated with
the gene expression of circulating proinﬂammatory
leukocytes, although this correlation was more
closely associated with metabolic activity of the
spleen.
The goal of the second study was to determine
whether the metabolic activity in the bone marrow
and spleen independently predicted cardiovascular
risk in a more stable atherosclerosis clinical scenario.
The study design was retrospective in nature and
involved the 6.5-year (median 4 years) follow-up of
464 patients who underwent routine clinical positron
emission tomography/computed tomography with
18F-ﬂuorodeoxyglucose for the diagnosis, staging, or
post-therapy evaluation of cancer. All patients were
either not diagnosed with cancer or were in remission
at the time of imaging and throughout the follow-up
interval. A broad deﬁnition of cardiovascular events
was used and included cardiac death; MI; ACS; heart
failure; revascularization of a coronary, carotid, or
peripheral bed; and stroke or transient ischemic
attack. In the entire patient cohort, both bone
marrow and splenic metabolic activity correlated
with arterial inﬂammation and with each other.
Over the median 4-year interval, 34 patients had a
cardiovascular event. A higher bone marrow 18F-
ﬂuorodeoxyglucose activity was associated with an
increased risk for cardiovascular events; however,
this association was no longer signiﬁcant after
adjustment for Framingham Risk Score. In contrast,
splenic 18F-ﬂuorodeoxyglucose activity was associ-
ated with cardiovascular increased risk, and this
association remained signiﬁcant after corrections
were made for various cardiac risk factors, Framing-
ham Risk Score, and key factors related to cancer
status, such as type of malignancy, timing of diag-
nosis, and type of therapy. Moreover, the association
remained signiﬁcant even after adjustment for arte-
rial inﬂammation.
Integrating the results of the 2 studies, the
authors concluded that splenic metabolic activity is
increased after ACS and correlates with arterial
inﬂammation, systemic inﬂammation, and proin-
ﬂammatory remodeling of circulating leukocytes.
Moreover, in a more stable cardiovascular popula-
tion, splenic activity is an independent predictor of
the risk of cardiovascular events. They suggest the
existence of this cardiosplenic axis may be clinicallyrelevant in both acute and stable atherosclerotic
disease.
The studies are very well done, and the results
provide a human correlate to pre-clinical studies and
expand on the aforementioned initial human obser-
vations. As pointed out by the authors, the conclu-
sions must be tempered by the potential confounding
effects of underlying cancer status on splenic
18F-ﬂuorodeoxyglucose activity and the increased
incidence of atherosclerosis in cancer survivors such
as those whose disease occurs at a younger age or
who receive mediastinal radiation. Moreover, the
retrospective nature of the study and the lack of
an intervention preclude the identiﬁcation of cau-
sality for the presence of the increased splenic
18F-ﬂuorodeoxyglucose for subsequent cardiovascu-
lar events.
That being said, the ﬁndings from this study are
provocative and raise the question of whether our
ﬁeld of view for imaging of atherosclerosis in the
clinical setting should be expanded to include
hematopoietic and extramedullary sites upstream
from the atherosclerotic plaque. Although this re-
quires further study, it may be that the presence of
splenic activity is a unique biomarker of increased
cardiovascular risk, particularly in certain patient
populations, such as the post-MI patient, in which
case such information may help identify patients
at increased likelihood for recurrent ischemia or
adverse left ventricular remodeling. Moreover, the
imaging of hematopoietic and extramedullary sites
may provide the means to evaluate novel cardiovas-
cular therapeutic agents designed to reduce the pro-
liferation, activation, or release of pro-inﬂammatory
monocytes. However, our ﬁeld of view will also need
to expand at the molecular level. Measurement of
metabolic activity in the spleen and bone marrow
with 18F-ﬂuorodeoxyglucose is nonspeciﬁc, because it
reﬂects the integration of signal arising from cellular
proliferation and activation of all metabolically active
cells. Given that monocyte subpopulations exhibit
diverse functions such as being proinﬂammatory or
enhancing cellular repair and yet are both likely
metabolically active, molecular imaging probes will
need to be developed that identify both the prolifer-
ation and activity of those monocyte subsets that
contribute to distinct components of the atheroscle-
rotic process.
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